BMO Capital initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Outperform rating and a price target of $57.00.Analyst M ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE